ClearNote Health's VP Translational Research & Head of Biopharma Development, Gulfem D. Guler, is attending the American Society of Clinical Oncology (ASCO) GU25 Symposium, February 13-15, San Francisco. Connect with Gulfem to learn more about ClearNote Health's...

ClearNote presented a poster entitled: “Cell-type specific signatures in plasma cell-free DNA 5-hydroxymethylome enables cancer detection and response monitoring in non-small cell lung cancer patients undergoing anti-PD-1 treatment.”

ClearNote presented a poster entitled: “Cancer-induced epigenomic changes in circulating immune cells enable breast, colorectal and lung cancer detection.”

ClearNote attended with booth (#6).

ClearNote Health presented findings from a clinico-economic analysis of its Avantect Pancreatic Test in a poster entitled “Cell-Free DNA Epigenomic-based Test is Predicted to Be Cost Effective to Manage New-Onset Type 2 Diabetes Patients for Risk of Pancreatic Cancer”...

ClearNote Health attended the 14th World CB & CDx Boston Summit. ... Virtuoso represents a paradigm shift in drug development, offering non-invasive testing, longitudinal research capabilities, and individualized patient epigenomics to reveal critical biological...

ADA took place in Orlando, FL., June 21–24, 2024. 

The American Society of Clinical Oncology (ASCO), took place in Chicago, May 31st - June 4th, 2024. We were present at our partner Personalis' booth #30149. If you missed us, contact us to learn more about how our proprietary, non-invasive 5hmC epigenomic platform...

We will be at Digestive Disease Week, Washington, DC, May 18th to 21st, 2024. Don't miss our presentation, titled: “Detection of High-Risk Pancreatic Cysts using Avantect™ blood-based test.” 

The American Medical Association CPT Editorial Panel Meeting took place in Chicago, May 9th to 11th, 2024.